Browse the corpus

Difelikefalin is a medication used to treat and manage uremic pruritis and postoperative pain, affecting patients' quality of life. Difelikefalin is in the opioid class of drugs and works as a selective kappa-opioid receptor agonist; alternative names for difelikefalin include 4-amino-1-(D-phenylalanyl-D-phenylalanyl-D-leucyl-D-lysyl)piperidine-4-carboxylic acid, CKD-943, MR13A9, FE202845, and CR 845. Since difelikefalin is peripherally selective, it is unlikely to cause lethal central nervous system adverse effects such as respiratory depression. IV dosing schedule after dialysis sessions enhances treatment logistics and patient outcomes. Moreover, difelikefalin presents as a safer alternative for managing postoperative pain amid the opioid crisis, offering decreased abuse potential and promising results in early trials. However, further research is needed to validate its efficacy and safety, especially in patients with diabetes and end-stage renal disease. This activity describes the mechanism of action, indications, administration, adverse effects, monitoring, and contraindications for difelikefalin therapy pertinent for interprofessional team members in treating patients with uremic pruritis or postoperative pain. Objectives: Identify patients with uremic pruritus and post-operative pain who may benefit from difelikefalin therapy. Screen patients for contraindications, potential drug interactions, and other factors that may impact the safe and effective use of difelikefalin. Assess the effectiveness of difelikefalin therapy in managing uremic pruritus and postoperative pain, monitoring treatment response, and adjusting the treatment plan as needed. Collaborate with other healthcare professionals, such as nephrologists, anesthesiologists, and pain management specialists, to ensure coordinated care and optimize the use of difelikefalin in managing uremic pruritus and post-operative pain. Access free multiple choice questions on this topic.

At supratherapeutic levels (15 mcg per mL), concern for respiratory depression or euphoric effects has not been demonstrated.[1][10] Difelikefalin has been studied in rats and determined to cause diuresis by activating central kappa opioid receptors.[17] Mild to moderate hypernatremia has been reported at supratherapeutic doses of 1.0, 2.0, and 5.0 mcg per kg. Any induced electrolyte imbalance observed during treatment should be managed per the standard of care in conjunction with the termination of medication administration and identification of any additional etiologies for the electrolyte disturbance.  The adverse effects mentioned previously, including hypoesthesia, paresthesia, and somnolence, are self-limiting at supratherapeutic doses.[10] No documented antidote for difelikefalin is currently in use. Considering the reassuring safety profile, the lack of activity in the CNS, and the more common adverse effects of difelikefalin subsiding without intervention, the clinical utility of naloxone in suspected supratherapeutic or toxic levels of difelikefalin is unlikely to be relevant. Phase 3 double-blind, randomized, placebo-controlled clinical trials have been conducted to study the use of difelikefalin for up to 8 and 12 weeks. The potential long-term effects of difelikefalin remain unclear.

The utility of a selective peripheral kappa opioid receptor agonist in treating uremic pruritis is emerging.[11] Patients with end-stage renal disease requiring dialysis face many challenges in preserving their quality of life. A coordinated effort by the nephrologist, dialysis nursing staff, patient family members, and primary care clinicians is necessary to address the uremic pruritis often experienced by these patients appropriately so that the negative impact on the patient is diminished.[18] Common practice can evolve from current therapy for uremic pruritis, which often ineffectively utilizes antihistamines or involves off-label use of gabapentin.[19][20][21] Understanding the mechanism of difelikefalin and how it effectively addresses the nonhistaminergic pathway that causes uremic pruritus is essential for the healthcare team to ensure that itching and the associated emotional distress often experienced by patients requiring dialysis may appropriately be addressed.[19][5] The IV dosing of difelikefalin, typically 3 times a week in IV bolus form after completing dialysis sessions, is logistically ideal, enhancing team performance and subsequent patient outcomes when rendering this treatment.[4] Further research clarifying the efficacy of difelikefalin in diabetes and end-stage renal disease patients would provide valuable insight for clinical decision-making as these conditions often co-exist.[22][21] The opioid crisis facing the healthcare industry today requires the introduction of safer postoperative pain medications with decreased abuse potential. Surgeons and primary care clinicians can initiate IV or oral difelikefalin for patients with acute postoperative pain or sub-acute and chronic pain, without significant concerns for lethal overdose or euphoric effects, even at supratherapeutic doses.[1] The extensive development of safer formulations of traditional oral opioid medications for pain management without the risk of misuse potential demonstrates a need that the novel difelikefalin oral formulation would fulfill through widespread implementation by healthcare providers.[21][1][14] Trials are currently underway to test difelikefalin for use in controlling postoperative pain; early results have shown promise regarding cost-effectiveness, clinical efficacy, and adverse event profile, but more research is necessary.[2]